Oct. 1 at 1:23 PM
$FBIO Stop comparing
$FBIO to
$UNCY.
$UNCY did a 1-for-10 reverse split right before its own vendor CRL, a combo that typically turbocharges downside.
$FBIO has a significantly longer cash runway than
$UNCY and screens closer to the
$SRRK “fixable manufacturing hiccup” (the plant has already addressed the FDA’s September re-inspection) than
$UNCY’s RS-amplified dump. Ultimately, we will see how the Market reacts today, but it's NOT the same situation as
$UNCY
